Jazz Fails Phase 3 Trial in Japan, BAT Set to See Growth From Cannabis Investment ...

Jazz Pharmaceuticals' Epidyolex failed Phase 3 trial in Japan; British American Tobacco invests in cannabis for growth; DanCann Pharma reports strong Q2 with record revenue and positive EBITDA.